On September 8, 2020 Zion Pharma Limited, an emerging Chinese biotechnology company focused on the development of brain-penetrable compounds, reported the initiation of its Phase 1 study, in the United States, for its lead program ZN-A-1041. ZN-A-1041, is a best-in-class, small molecule tyrosine kinase receptor inhibitor targeting HER2 (Press release, Zion Pharma, SEP 8, 2020, View Source [SID1234564778]). ZN-A-1041 is being developed to address the unmet medical need associated with brain metastases accompanying HER2+ advanced breast cancer. The U.S. trial is being conducted at several sites including the Dana Farber Cancer Institute and the Duke Cancer Institute.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to have initiated our Phase 1 trial for ZN-A-1041," stated Zack Cheng, Ph.D., Chairman, CEO and Co-Founder at Zion Pharma Limited. "With dosing of the first patient in our Phase 1 study, Zion becomes a clinical stage company. A feat we are particularly proud of as we achieved this within 30 months of forming the company." Dr. Cheng continued, "We recently completed a $20 million Series A follow-on that will provide us sufficient funding for the next two years. This is an extremely exciting time for our team, and we look forward to advancing highly effective therapies to those patients in need."

Dr. Ding Zhou, Ph.D., CSO and Co-Founder, at Zion Pharma Limited added, "With our recent financing, we expect to complete the ZN-A-1041 Phase 1 study in the U.S. and China and advance several of our other programs into IND-enabling studies."

In addition, the company announced that Wendy Li, M.D. has joined the company as Chief Medical Officer. Dr. Li brings to Zion Pharma 10 years of clinical practice and over 20 years of hands-on experience in providing medical and scientific leadership in clinical research multiple therapeutic areas, with previous experience in oncology clinical development at Genentech, Sanofi, and Pfizer. Previously, Dr. Li has been VP/CMO with Sihuan Pharma/Xuanzhu Shandong and CMO at Exuma Biotech. Dr. Li received her M.D. from the Sun Yat-Sen University of Medical Studies in China.

On September 8, 2020 OncoImmune, Inc. reported the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor (Press release, ONCOIMMUNE, SEP 8, 2020, View Source [SID1234564777]). Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new investors, GBA Fund and GF Xinde, also joined the round. Oncoimmune will use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncoImmune currently has two Phase III clinical programs to evaluate its lead product CD24Fc, a first-in-class biologic, in protecting against immune destruction in severe and critical COVID-19 patients in one trial, and in leukemia patients that are prone to acute GVHD after receiving allogeneic hematopoietic stem cell transplant in the second trial. The COVID-19 Phase III trial has been initiated in 17 medical centers nationwide and is enrolling severe and critical COVID-19 patients that either require supplemental oxygen support or high flow oxygen non-invasive ventilation, in addition to ICU patients requiring invasive mechanical ventilation. The trial plans to enroll over 270 patients and is near its enrollment target with topline readouts expected soon.

"We are grateful to our investors for their confidence and continued support," said Yang Liu, PhD, Founder, CEO and Chairman of OncoImmune. "We are delighted to see the significant progress OncoImmune has made in the past few years. It exemplifies how great scientific discovery can be turned into potential novel therapeutics benefiting patients," said Dr. Karen Liu, Partner at 3E Bioventures Capital, which led OncoImmune’s Series A round in 2017.

"HM Capital is delighted to co-lead the investment to support innovations of transformative impact. We very much look forward to OncoImmune’s continuous success," said Robert Luo, the founding partner of HM Capital.

On September 8, 2020 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:30 a.m. EDT on Tuesday, Sept. 15, at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference will be held virtually (Press release, Puma Biotechnology, SEP 8, 2020, View Source [SID1234564776]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

On September 8, 2020 Exelixis, Inc. (Nasdaq: EXEL) reported that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in September (Press release, Exelixis, SEP 8, 2020, View Source [SID1234564775]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 18th Annual Global Healthcare Conference: Exelixis is scheduled to present at 3:30pm EDT / 12:30pm PDT on Tuesday, September 15, 2020.
BofA Securities Global Healthcare Conference 2020: Exelixis is scheduled to present at 5:35pm BST (British Summer Time) / 12:35pm EDT / 9:35am PDT on Wednesday, September 16, 2020.
Cantor 2020 Virtual Global Healthcare Conference: Exelixis is scheduled to present at 4:40pm EDT / 1:40pm PDT on Wednesday, September 16, 2020.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

On September 8, 2020 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported the company will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 10:30 a.m. ET/7:30 a.m. PT (Press release, Alpine Immune Sciences, SEP 8, 2020, View Source [SID1234564774]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.